425: Runway Growth to Acquire SWK Holdings, Boosts Healthcare

Runway Growth Finance Corp. announces a definitive merger agreement to acquire SWK Holdings Corporation, aiming to diversify its portfolio and expand in healthcare and life sciences.

Summary

• Runway Growth Finance Corp. (RWAY) has entered into a definitive merger agreement with SWK Holdings Corporation (SWKH).
• The transaction is structured as a NAV-for-NAV merger, a tax-free reorganization.
• The estimated purchase price is approximately $220 million, comprising ~$145 million in cash and ~$75.5 million in RWAY shares (approximately 15% of RWAY's shares post-merger).
• Runway Growth Capital LLC, RWAY's external investment adviser, will make an additional $9 million cash payment to SWK stockholders.
• The anticipated closing is late Q4-2025 or early Q1-2026.
• The acquisition is expected to grow RWAY's healthcare portfolio, add key investment team members, and increase Net Investment Income (NII) levels.
• Post-transaction, healthcare and life sciences will represent approximately 31% of RWAY's total loan portfolio, up from 14% at the end of Q2-2025.
• The combined entity is projected to have approximately $1.267 billion in investments at fair value, 76 portfolio companies, and an average funded loan size of $27.7 million.

Sentiment

Score: 8

Explanation: The filing outlines a strategic acquisition expected to significantly enhance Runway Growth's portfolio, financial profile, and market position, particularly in the resilient healthcare and life sciences sectors. The anticipated NII accretion, improved liquidity, and reduced risk profile are strong positives, despite inherent merger risks.

Positives

• Optimizes the portfolio through diversification and scale.
• Expands into attractive industry sectors like healthcare and life sciences.
• Capitalizes on the benefits of the BC Partners Credit platform.
• Increases NII levels to ensure consistency in capital allocation strategy.
• Adds high-quality, complementary investments to Runway's existing structure.
• Meaningfully reduces the company's average loan size from $32.7 million to $27.7 million.
• Solidifies RWAY's position as a lender to the large and growing healthcare and life sciences market, increasing portfolio percentage from 14% to approximately 31%.
• Enhanced scale is expected to drive further RWAY fixed cost absorption.
• Trading liquidity is expected to improve with a broadened shareholder base and increased market cap.
• Lower risk profile supported by the average loan position declining to approximately 2%.
• Reduced funding cost plus increased viability of accessing ABS and other credit markets.
• More efficient use of leverage expands ROE and NII profile, contributing to expanded base dividend coverage.
• Anticipates mid single-digit run-rate NII accretion during the first full quarter following closing.
• SWK's team brings extensive healthcare and life sciences experience and a strong track record in origination.
• SWK's focus on FDA-approved assets offers limited downside and superior risk-adjusted returns.

Risks

• Uncertainties associated with the ability of the parties to consummate the merger on the expected timeline, or at all.
• Uncertainties regarding the expected synergies and savings associated with the merger.
• Ability to realize the anticipated benefits of the merger, including the expected elimination of certain expenses and costs.
• Impact of the merger on the depth of trading in Runway's shares of common stock post-closing.
• Possibility that any or all of the various conditions to the consummation of the merger may not be satisfied or waived.
• Risks related to diverting management's attention from ongoing business operations.
• Risks related to the combined company's plans, expectations, objectives, and intentions.
• Any potential termination of the merger agreement.
• Risks related to the future operating results and net investment income projections of the combined company.
• Ability of Runway Growth Capital LLC to implement its future plans with respect to the combined company.
• Ability of Runway Growth Capital LLC and its affiliates to attract and retain highly talented professionals.
• Risks related to the business prospects of the combined company and its portfolio companies.
• Risks related to expected financings and investments and additional leverage that the combined company may seek to incur in the future.
• Adequacy of the cash resources and working capital of the combined company.
• Risk that stockholder litigation in connection with the merger may result in significant costs of defense and liability.

Future Outlook

Runway Growth Finance anticipates the acquisition to generate mid single-digit run-rate Net Investment Income (NII) accretion during the first full quarter following the closing of the transaction. The combined company expects enhanced scale to drive further fixed cost absorption, improved trading liquidity, a lower risk profile due to reduced average loan position, and more efficient use of leverage to expand ROE and NII profile, contributing to expanded base dividend coverage. The company also expects reduced funding costs and increased viability of accessing ABS and other credit markets.

Management Comments

• The transaction advances Runway Growth's strategy to optimize its portfolio through diversification and scale.
• The company aims to expand in attractive industry sectors like healthcare and life sciences.
• The acquisition will capitalize on the benefits of the BC Partners Credit platform.
• The company intends to increase NII levels to ensure consistency in its capital allocation strategy.

Industry Context

The acquisition positions Runway Growth as a significant lender in the growing healthcare and life sciences market, a sector characterized by pervasive demand minimally correlated with economic cycles. SWK's expertise in FDA-approved assets with high barriers to entry aligns with a strategy for defensible assets and attractive risk-return profiles, leveraging specialized knowledge in a high-growth, resilient industry. The combined platform's AUM of ~$10 billion and global investment exposure across 8 offices positions it as a major player, significantly larger than its closest standalone venture debt peer.

Comparison to Industry Standards

• The combined platform's AUM of ~$10 billion is stated to be 'Over 2x the closest standalone venture debt peer,' indicating a significant competitive advantage in scale.
• SWK's historical focus on $5-25 million financings with unlevered, mid-teens gross returns suggests a strong performance in its niche, which Runway aims to integrate and leverage.
• The emphasis on secured financings (primarily first-lien, senior secured, floating-rate loans with covenants, prepayment penalties, origination/exit fees, and warrants) aligns with prudent lending practices in the specialty finance sector, aiming for enhanced economics through better pricing, lower leverage, tighter covenants, and downside protection.

Management Changes

Related Party Transactions

• Runway Growth Capital LLC, RWAY's external investment adviser, will make a $9 million cash payment to SWK stockholders as part of the merger consideration.

Stakeholder Impact

• Shareholders (RWAY): Expected NII accretion, improved trading liquidity, increased market cap, diversified portfolio, lower risk profile, and expanded base dividend coverage.
• Shareholders (SWK): Will receive cash and RWAY shares as consideration for the merger.
• Employees (SWK): Key members of SWK's investment team are expected to join Runway Growth, integrating their expertise.
• Customers/Portfolio Companies: The combined entity offers a larger platform and potentially enhanced financing solutions.

Next Steps

• File a Combined Proxy Statement and Prospectus with the SEC.
• SWK stockholders are urged to read the Combined Proxy Statement and Prospectus and other SEC filings.
• Consummate the merger, anticipated late Q4-2025 or early Q1-2026.

Key Dates

Recommendation

The acquisition is highly strategic, immediately accretive to NII, and significantly diversifies the portfolio into a high-growth, resilient sector. The enhanced scale, improved liquidity, and reduced risk profile, coupled with the expertise gained, position Runway Growth for substantial long-term value creation. The pro-forma leverage moving up to ~1.1x is manageable and indicates efficient capital deployment.

Keywords

Runway Growth Finance, SWK Holdings, Merger, Acquisition, Healthcare Finance, Life Sciences, BDC, Business Development Company, Portfolio Diversification, NII Accretion, BC Partners Credit, RWAY, SWKH